Table 2 The comparison of clinical variables between MAPK14-high and MAPK14-low groups, which were also performed for over-expression/under-expression subgroups of JAK2, EPOR, STAT5A and STAT5B. The p value ≤ 0.05 was in boldface
|  | MAPK14 low (n = 10) | MAPK14 high (n = 10) | p value (MAPK14-high vs low subgroups) | p value (JAK2-high vs low subgroups) | p value (EPOR-high vs low subgroups) | p value (STAT5A-high vs low subgroups) | p value (STAT5B-high vs low subgroups) |
|---|---|---|---|---|---|---|---|
Age (year) | 65.5 | 63.1 | 0.579 | 0.481 | 0.281 | 0.393 | 0.796 |
JAK2 mutation burden (%) | 78.9 | 90.5 | 0.19 | 0.739 | 0.393 | 0.52 | 0.739 |
Initiation of drug therapy (%) | 10 | 80 | 0.005 | 0.37 | 0.37 | 1 | 1 |
Hemoglobulin (g/dL) | 13.1 | 11.62 | 0.063 | 0.684 | 0.796 | 0.853 | 0.631 |
Leukocyte count | 16706 | 35999 | 0.529 | 0.631 | 0.684 | 0.19 | 1 |
Platelet count | 741.3 | 648.5 | 0.684 | 0.971 | 0.19 | 0.853 | 0.971 |
Splenectormy (%) | 0 | 50 | 0.033 | 1 | 1 | 1 | 1 |
Thrombosis (%) | 0 | 50 | 0.033 | 1 | 1 | 1 | 1 |
AML transformation (%) | 10 | 40 | 0.303 | 1 | 1 | 1 | 1 |
Disease aggressiveness (%) | 0 | 70 | 0.003 | 1 | 1 | 1 | 1 |
Survival (%) | 90 | 40 | 0.05 | 1 | 0.35 | 1 | 1 |